Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells

Published:2013-09 Issue:9 Volume:4 Page:e814-e814
ISSN:2041-4889
Container-title:Cell Death & Disease
language:en
Short-container-title:Cell Death Dis

Author:

Chen J,Bi H,Hou J,Zhang X,Zhang C,Yue L,Wen X,Liu D,Shi H,Yuan J,Liu J,Liu B

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology

Link

http://www.nature.com/articles/cddis2013312.pdf

Reference35 articles.

1. Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11–22.

2. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.

3. Cox AD, Der CJ . Ras family signaling: therapeutic targeting. Cancer Biol Ther 2002; 1: 599–606.

4. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale C M et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006; 116: 2695–2706.

5. Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M, Izumi H et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 2010; 70: 8715–8725.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health;Applied Biochemistry and Biotechnology;2023-10-28

2. New insights into the therapeutic potentials of statins in cancer;Frontiers in Pharmacology;2023-07-07

3. Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing;BMC Bioinformatics;2023-05-24

4. Inhibitory effect of obatoclax mesylate-Loaded nanoparticles on lung cancer through Bcl-2 pathway;Materials Express;2023-02-01

5. A review of effects of atorvastatin in cancer therapy;Medical Oncology;2022-12-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3